3M has entered into an agreement to sell its drug delivery business to an affiliate of Altaris Capital Partners, LLC for approximately $650 million.   The global drug delivery business partners with pharma and biopharma companies to develop and manufacture pharmaceutical products using inhalation, transdermal, microneedle, and conventional drug delivery technologies. 3M will retain its transdermal drug delivery components business. The business that is being divested has annual global sales of...